Foresight Group Ltd Liability Partnership Buys New Stake in Genmab A/S Sponsored ADR $GMAB

Foresight Group Ltd Liability Partnership acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 48,725 shares of the company’s stock, valued at approximately $954,000.

Several other institutional investors have also modified their holdings of the stock. Marotta Asset Management boosted its stake in Genmab A/S by 5.8% during the first quarter. Marotta Asset Management now owns 13,532 shares of the company’s stock worth $265,000 after buying an additional 739 shares during the period. Gallacher Capital Management LLC lifted its holdings in shares of Genmab A/S by 6.8% in the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock worth $281,000 after acquiring an additional 915 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after purchasing an additional 1,070 shares during the period. Smartleaf Asset Management LLC grew its holdings in Genmab A/S by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 5,772 shares of the company’s stock valued at $115,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Headlands Technologies LLC raised its position in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after purchasing an additional 1,464 shares during the period. 7.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on GMAB shares. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 28th. HC Wainwright upped their price objective on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Truist Financial lifted their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Finally, Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $27.73 on Thursday. The stock has a market cap of $17.79 billion, a price-to-earnings ratio of 13.93, a PEG ratio of 1.62 and a beta of 0.93. The firm’s 50-day moving average is $23.24 and its two-hundred day moving average is $21.57. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.03.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.